Inglasia provides comprehensive EU pharmaceutical importation services for companies seeking legal, compliant entry of medicinal products into the European Union. Every import we manage operates under a valid Manufacturer Importation Authorisation (MIA) License, ensuring that your products meet all regulatory requirements before reaching the EU market.
Our team oversees the full import pathway, including document verification, compliance checks, and coordination with EU authorities. This service is compliance-driven, structured to guarantee that every shipment aligns with EU GMP standards and Marketing Authorisation. It is not a QP batch release, storage, or distribution service—our focus is on legal importation and regulatory adherence.
With Inglasia as your partner, you gain a reliable route to EU market access. We ensure that your imports are processed efficiently, legally, and with full regulatory accountability. Every batch that enters the EU under our management is traceable, documented, and ready for downstream certification and market release.
Partner with us today to secure your pharmaceutical imports into Europe. Let us manage the legal import pathway so you can focus on your business growth and market expansion.
EU pharmaceutical importation is the legal process of bringing medicinal products into the European Union under full regulatory compliance. It ensures that all imported products meet EU quality, safety, and marketing requirements before they enter the market. This process is governed by the Manufacturer Importation Authorisation (MIA), which legally permits companies to import medicines from non-EU manufacturers into the EU.
The MIA outlines responsibilities for compliance with EU GMP standards, traceability, and inspection readiness. Through this authorisation, Inglasia manages the importation pathway, verifying that every shipment has complete documentation, meets technical standards, and aligns with your Marketing Authorisation. The MIA ensures that imported products are legally cleared for subsequent release and distribution within the EU.
It is important to note what EU pharmaceutical importation is not. This service does not cover QP batch release, certification under Annex 16, or the verification of individual batches. It is also not a storage or distribution service. The focus is purely on legal, MIA-authorised importation and compliance with EU law.
By relying on Inglasia for your import needs, your products are imported under a structured, compliant framework that meets all regulatory requirements and positions your business for smooth downstream release and market access.
Our EU pharmaceutical importation services follow a structured, compliance-focused process to ensure that every shipment meets legal requirements and is ready for the European market.
We begin by verifying all manufacturer records, including batch production data, certificates of analysis, and quality documentation. This ensures that the products are manufactured in compliance with international GMP standards and meet the conditions of your Marketing Authorisation.
Next, we conduct a detailed compliance check to confirm that all documentation, labeling, and shipment details align with EU regulatory requirements. This step includes technical compliance checks and verification, ensuring batches are EU importation tested by our Qualified QC Vendors. This step ensures traceability, reduces risk of non-compliance, and prepares the shipment for inspection by EU authorities if required.
With all documentation verified, we manage the import under a valid Manufacturer Importation Authorisation (MIA) License. This legal framework allows your products to enter the EU, ensuring full adherence to EU GMP, safety, and quality regulations.
Once imported, your products are cleared for the next steps in the supply chain. While Inglasia does not perform storage or distribution, we ensure that the imported batches are fully compliant and ready for downstream release, including QP batch certification if required.
Our stepwise approach provides a transparent, legally compliant import pathway for medicinal products, giving you confidence in seamless EU market access.
Contact us now
Ireland provides a strategic and highly regulated gateway for importing medicinal products into the European Union. As an EU Member State, it offers full access to the EU single market, enabling companies to distribute their products efficiently across all member countries once legally imported.
Our facilities in Ireland operate under a robust regulatory framework, ensuring that every shipment complies with EU GMP standards and MIA requirements. This regulatory stability and competence give companies confidence that their imports meet European legal obligations and are fully prepared for downstream certification and release.
By managing imports through Ireland, we provide a seamless integration with the broader EU Import & Batch Release pathway. Imported batches can move directly into QP certification, technical review, and eventual market release, all under a structured, compliant framework.
Partnering with Inglasia for Irish import operations allows your business to benefit from strategic EU positioning, regulatory assurance, and streamlined access to the European market, while aligning imports with your broader compliance and market entry strategy. Our facilities are designed to support efficient, legally compliant, and audit-ready import processes, giving you confidence in every batch that enters the EU.
EU pharmaceutical importation is strictly regulated to ensure the safety, quality, and compliance of all medicinal products entering the market. Inglasia’s services operate under a Manufacturer Importation Authorisation (MIA) License, which provides legal authorisation to import medicines into the EU and sets out the responsibilities of the importer.
All imports must comply with EU Good Manufacturing Practice (GMP) standards, covering manufacturing, quality control, documentation, and traceability. Our processes ensure that every shipment meets these standards before entering the EU, reducing risk and ensuring full regulatory adherence.
Oversight by the European Medicines Agency (EMA) and national competent authorities ensures that imported products are safe, properly documented, and traceable at every stage. Inglasia aligns its import procedures with these requirements, maintaining detailed records, batch traceability, and audit-ready documentation for each shipment.
Our structured compliance framework covers legal responsibilities, regulatory reporting, and alignment with inspections. Each import is verified against GMP standards and the conditions of your MIA, providing a transparent, accountable, and compliant pathway to the EU market. You can rely on us to manage the full regulatory framework for imports, ensuring products are legally authorised, traceable, and ready for downstream certification or market release.
We offer a complete range of pharmaceutical importation services designed to ensure your medicinal products enter the EU legally, compliantly, and efficiently. Each service operates under the Manufacturer Importation Authorisation (MIA) framework and aligns with EU GMP standards, thereby providing a clear, regulated pathway to market.
We manage the importation of finished medicinal products from non-EU manufacturers. Our team verifies all production and quality documentation, ensuring that each shipment meets EU regulatory requirements. This service integrates seamlessly with downstream certification, allowing your products to proceed toward market release under our EU Import & Batch Release services.
Our drug importation services cover active pharmaceutical ingredients (APIs) and other critical drug components. We coordinate with manufacturers, confirm compliance with labeling and safety standards, and ensure that all regulatory documentation is complete and accurate for EU entry.
We assist with the full administration of your MIA licence, maintaining compliance with EU authorities and ensuring that your import authorisation is valid and up to date. This includes renewals, regulatory filings, and ongoing oversight to guarantee uninterrupted EU market access.
All of our importation services are structured to provide regulatory certainty, compliance assurance, and operational efficiency. Once imported, batches can be fully certified through our Qualified Person (QP) batch release services, ensuring a smooth transition from legal import to EU market availability. Partnering with Inglasia allows you to import confidently, stay compliant, and access the EU market without regulatory risk.
Inglasia’s EU pharmaceutical importation services support companies that need a regulated and compliant pathway into the European market.
Non-EU Marketing Authorisation Holders (MAHs) rely on our services to legally import products manufactured outside the EU, ensuring compliance with all MIA and EU GMP requirements.
Virtual pharmaceutical companies benefit from our structured import processes, allowing them to operate efficiently without needing their own EU regulatory infrastructure.
Biotech sponsors moving from development to commercial supply use our services to guarantee that imported products meet EU quality, safety, and regulatory standards before market release.
Contract manufacturers (CMOs/CDMOs) leverage our expertise to manage legally compliant importation of products on behalf of their clients, providing peace of mind and regulatory certainty.
Clinical sponsors entering the EU market can depend on our framework to import investigational medicinal products safely and legally, ensuring that all shipments meet regulatory requirements.
By partnering with Inglasia, you gain a reliable, compliant import pathway, from documentation verification to MIA-authorised EU entry, ensuring that every shipment is fully prepared for subsequent certification and market release.
Companies choose Inglasia for EU pharmaceutical importation because our services combine legal authority, regulatory expertise, and operational reliability. We hold a valid Manufacturer Importation Authorisation (MIA), providing a licensed framework for importing medicinal products into the EU. This ensures every shipment is fully compliant with EU law and GMP standards.
Our team has extensive experience managing imports under complex regulatory requirements, providing audit-ready processes that support inspections and demonstrate full traceability. Each shipment undergoes verification against manufacturer documentation, labeling, and quality standards, giving clients confidence that products are legally authorised and compliant before reaching the EU market.
Risk control is a core part of our service. We identify potential compliance issues early, address gaps proactively, and maintain detailed records for each batch. This structured approach reduces regulatory and operational risk while ensuring smooth market entry.
By partnering with Inglasia, companies gain a commercially reliable and legally accountable import solution. Our framework allows businesses to focus on growth and market expansion while knowing their imports are handled under a fully compliant, inspection-ready process. From documentation verification to MIA-authorised EU entry, every step is managed with precision, regulatory authority, and accountability.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
A Manufacturer Importation Authorisation (MIA) licence is a legal requirement that allows companies to import medicinal products into the European Union from non-EU countries. It confirms that the importing entity meets EU GMP standards and is authorised to handle pharmaceutical imports under regulated conditions.
Yes. Any medicinal product manufactured outside the EU must be imported through an entity holding a valid MIA licence. Without this authorisation, products cannot legally enter the EU pharmaceutical supply chain.
Importation involves verifying manufacturer documentation, certificates of analysis, batch records, and compliance with EU GMP and Marketing Authorisation requirements. These checks ensure that products meet regulatory standards before entering the EU.
No. EU importation and QP batch release are separate regulatory steps. Importation under an MIA licence allows products to enter the EU, while QP certification is required afterward to approve each batch for market release.
Yes. Non-EU companies can partner with an authorised MIA licence holder to manage the import process on their behalf. This provides a compliant route to EU market entry without the need to establish their own licensed entity.
Secure your EU market access with Inglasia, your EU import and batch release partner. Our MIA-authorised import services ensure that every medicinal product entering the European Union is fully compliant, traceable, and ready for downstream certification and release.
Whether you are a non-EU MAH, a biotech sponsor, or a contract manufacturer, our structured import processes provide regulatory assurance, audit-ready documentation, and operational reliability.
Next Steps:
Contact our team to discuss your import requirements.
Schedule a consultation to align your shipments with EU compliance standards.
Integrate your import pathway with our EU Import & Batch Release services for a complete, legally compliant route to market.
With Inglasia handling the regulatory framework, every shipment is processed efficiently and confidently, giving your business a secure and compliant path into the European market.
